SAN DIEGO--(BUSINESS WIRE)--Akesis Pharmaceuticals, Inc. (OTCBB:AKES), an emerging diabetes drug-development company, today announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for AKP-020, a novel vanadium compound, to test its safety and efficacy in patients with Type 2 Diabetes. dgd Research, Inc. of San Antonio has begun screening patients in a Phase IIa, controlled U.S. clinical trial measuring efficacy (using the gold-standard euglycemic-hyperinsulinemic clamping procedure), as well as pharmacokinetic parameters, safety and tolerability of AKP-020 in diabetic patients.
